In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

AZ and MedImmune get exclusive rights from Innate; deal expanded

Executive Summary

AstraZeneca PLC and its biologics division MedImmune LLC licensed exclusive global rights to develop and sell a cancer therapy combining their MEDI4736 with Innate Pharma SA’s IPH2201. AZ also gets access to IPH2201 as a monotherapy and combo treatment in other undisclosed areas.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register